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Secretion of insulin-like growth factor I and its binding proteins by
collecting duct cells. Insulin-like growth factor I (IGF-I) has been found
in the kidney, particularly in the collecting duct in the rat. Since
cultured rabbit collecting duct cells constitute a convenient system for
in vitro studies, we have examined whether these cells secrete IGF-I.
Culture medium conditioned by collecting duct cells was concentrated
by reverse phase chromatography and applied to a Sephadex G100
column equilibrated in a denaturing buffer. Two major species with
apparent molecular weights of 7.5 and greater than 25 kilodaltons (kD)
were identified by IGF-I RIA. A smaller amount of 10 kD species was
also observed. Further characterization of 7.5 kD IGF-I immunoreac-
tive species by reverse phase HPLC showed that it eluted in a single
peak. To determine whether the higher molecular weight species
possessed IGF-I binding activity, appropriate fractions were desalted,
incubated with ['251]IGF-I (thr59) for two hours at 30°C and applied to
a Sephadex Gl00 column equilibrated in a non-dissociating buffer. The
major peak of radioactivity was confined to a high molecular weight
region; there was no radioactivity in the fractions corresponding to 7.5
kD. Western ligand analysis of unreduced conditioned medium identi-
fied two IGF-I binding species of 25 and 30 kD, similar in size to species
observed in normal rabbit serum. '251-IGF-I binding as assessed in a
charcoal adsorption assay could be displaced by IGF-I and IGF-Il but
not by insulin. Further characterization of the 10 kD peak of IGF-I
immunoreactivity indicated that it did not possess IGF-I binding
activity. In addition, its size was not affected by reduction of disulfide
bonds. We conclude that cells cultured from rabbit collecting duct
secrete: (1) IGF-I; (2) a high molecular weight IGF-I-containing species;
and (3) IGF-I binding proteins. Since proximal tubular cells and
mesangial cells possess specific IGF-I receptors, these data suggest that
IGF-I may act as paracrine factor that regulates renal growth and/or
function.
The insulin-like growth factors constitute a family of growth-
promoting polypeptides. Insulin-like growth factor I (IGF-I) is a
70-amino acid peptide with structural homology to proinsulin
[11. Traditionally, IGF-I has been thought to mediate the effects
of growth hormone by acting as a classic endocrine hormone on
target tissues distant from its major source, the liver. However,
IGF-I has been found in a wide variety of tissues suggesting that
IGF-I also acts as an autocrine or paracrine factor [2—5]. Unlike
most peptide hormones, IGF-I circulates bound to specific
proteins [61. These IGF binding proteins which are also synthe-
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sized in a variety of tissues modulate the activity of IGF-I [7—91.
Recent studies have identified IGF-I peptide by immunohisto-
chemistry and IGF-I mRNA species in the collecting duct of the
rat kidney [10—12]. Since cultured renal tubular cells constitute
a useful model system for the study of tubular pathophysiology,
we examined whether collecting duct cells secrete IGF-I. Our
characterization of IGF-I immunoreactivity in culture medium
from rabbit collecting duct cells indicates that these cells
secrete both IGF-I and IGF-I binding proteins.
Methods
Collecting duct cell cultures
Renal tubular epithelial cells were isolated and cultured as
previously described [13, 14]. Briefly, 2 kg male New Zealand
White rabbits were killed using nitrogen gas. The kidneys were
removed and placed in cell culture medium during transport.
Each kidney was perfused with 10 to 20 cc of Collins solution
with 5 m ethylene glycol-bis-(8-amino-ethylether) N,N-tetra-
acetic acid until free of blood. The cortex was minced and
homogenized (four strokes) with a Dounce homogenizer (loose
pestle). The homogenate was poured over a series of nylon
mesh screens (250 j. to 20 ) which removed glomeruli and
intact tubules. The isolated cells, which passed through the 20
filter (average yield 25 to 40 x io cells), were pelleted by
centrifugation at 200 x g and layered on a discontinuous Peroll
gradient of 30 to 60% (Pharmacia, Piscataway, New Jersey,
USA) which was spun at 1500 x g for 15 minutes. Cell fractions
(least dense) from the gradient were cultured as described by
Chung et al [131, employing media containing a 50:50 mixture of
Dulbecco's Modified Eagle medium (DME, Gibco, Grand Is-
land, New York, USA) and Ham's Fl2 (Gibco) supplemented
with 15 ms's N-2-hydroxyethylpiperazine-N '2-ethanesulfonic
acid (Hepes; Sigma Chemical Co., St. Louis, Missouri, USA)
buffer, 1.2 mg/mI sodium bicarbonate, 192 IU/ml penicillin, 200
jig/mI streptomycin, 5 jig/mI bovine insulin, S jig/ml human
transferrin, and 5 x l0— M hydrocortisone, with the addition of
5% fetal bovine serum. Freshly isolated cells were plated at a
high density, 0.2 x 106 cells/cm2, to discourage dedifferentia-
tion and maintained in a humidified incubator 5% CO2/95% air
at 37°C. Morphologic characteristics of the epithelial cells have
been studied. Electron micrographs have demonstrated that the
collecting duct cells as recovered from the Percoll density
gradient (density = 1.019 to 1.023 gIml) display typical charac-
teristics of a large nucleus to cytoplasmic ratio, no microvilli,
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and relatively few mitochondria [141. Following short-term
maintenance in culture, cells retain arginine vasopressin stim-
ulation of cAMP and PGE2 production, important distinguish-
ing features of this nephron segment [14—16]. In addition,
bradykinin mobilizes rises in cytosolic Ca2 through activation
of phospholipase C and release of inositol phosphates [14].
Cells from passages 2 to 5 were used after being grown to
confluency.
Radioimmunoassay
IGF-I immunoreactivity was assayed as previously reported
[171. The RIA utilized antiserum UBK487, from Drs. Louis
Underwood and Judson J. Van Wyk, distributed by the Hor-
mone Distribution Program of the NIDDK through the National
Hormone and Pituitary Program. The antiserum has 0.5% cross
reactivity with IGF-I1 and minimal cross reactivity with insulin
at l06 mol/liter. Recombinant human IGF-I, purchased from
Collaborative Research (Bedford, Massachusetts, USA), was
used as a standard. '251-[3-tyrosyl-]IGF-I (thr59), abbreviated
as '251-IGF-I, was obtained from Amersham Corp. (Arlington
Heights, Illinois, USA). Standards and unknowns were incu-
bated in duplicate with antibody for two hours at room temper-
ature prior to addition of '25I-IGF-I. After overnight incubation,
the antibody-bound '251-IGF-I was precipitated using goat
anti-rabbit gamma globulin and normal rabbit serum as carrier.
All fractions from a column were assayed in a single RIA either
directly or after lyophilization of volatile buffers and redissolv-
ing in assay buffer. Each chromatographic procedure was
performed twice and similar results were obtained on each
occasion.
Secretion experiments
Collecting duct cells grown to confluence in 6-well dishes in
serum-containing medium were washed and cultured in serum-
free, insulin-free medium. After 24 hours, the cultures were
washed and fresh serum-free insulin-free medium was added.
Culture medium conditioned for 24 hours in the absence or
presence of io M cycloheximide was then assayed for IGF-I
immunoreactivity by RIA. Cells were trypsinized and counted
in a Coulter counter (Coulter Electronics, Hialeah, Florida,
USA).
Gel filtration chromatography
Collecting duct cells were grown to confluence in 75 cm2
flasks and treated as above. After 48 hours in serum-free,
insulin-free medium, the conditioned medium from six flasks
was pooled and passed over a 500 mg octadecylsilane silica
column (Vydac, Hesperia, California, USA); the column then
was eluted with 90% acetonitrile in 0.1% aqueous trifluoroacetic
acid and the resulting eluates dried [171. The dried residues
were dissolved in 6 mol/liter guanidine HCI, 0.03% Brij and
applied to a (0.7 x 45 cm) column of Sephadex GlOO equili-
brated in 6 mol/liter guanidine HCI, 0.03% Brij. The column was
calibrated with a series of standards, including blue dextran,
cytochrome c (molecular wt 12.4 kD), and '251-IGF-I. The
recovery of applied radioactivity was greater than 90%. Reduc-
tion of disulfide bonds of 10 kD IGF-I immunoreactive moieties
was achieved by incubation with 2-mercaptoethanol (final con-
centration 5%, vollvol) at 70°C x one hour. These moieties
were then rechromatographed on the 0.7 x 45 cm Sephadex
G75 superfine column equilibrated in 6 mollliter guanidine
HCIIO.03% Brij. Fractions from the guanidine column were
desalted by reverse phase chromatography as above. The
eluates were then dried and the residues redissolved in 50
mmol/liter phosphate-buffered saline, pH 7.4 and incubated
with '251-IGF-I at 30°C for two hours in the absence or presence
of excess unlabeled IGF-I. The samples were then chromato-
graphed on a 0.7 x 45 cm Sephadex GlOO column equilibrated
with phosphate-buffered saline and calibrated as above. The
radioactivity of the fractions was determined using a gamma
counter. Recovery of applied radioactivity was greater than
90%.
High performance liquid chromatography (HPLC)
The 7.5 kD peak from the initial Sephadex Gl00 column
(peak I from Fig. 2) was analyzed by HPLC using a modular
system consisting of a Spectra Physics 8700 solvent delivery
system, a Waters Associates U6K injector, and a Kratos UV
detector. The gel filtration fractions (300 jd) were injected onto
a Cl8 analytical column (Vydac, The Separations Group,
Hesperia, California USA)[ 171. An acetonitrile-water gradient
containing 0.1% trifluoroacetic acid was used. The flow rate
was 1 mI/mm; 1 ml fractions were collected, dried and the
residues were dissolved in RIA buffer.
Charcoal adsorption assay for IGF-I binding activity
A modification of the method of Martin and Baxter was used
to measure IGF-I binding activity [18]. Duplicate or triplicate
aliquots of serum-free, insulin-free conditioned media were
incubated with '25I-IGF-I (10,000 cpm) in a final volume of 500
d of 50 mrvi Tris-HC1, 0.1% bovine serum albumin (Sigma
Chemical Co.), pH 7.4. After two hours incubation at room
temperature 1% activated charcoal (Sigma Chemical Co.) with-
out protamine was added to the tubes followed by incubation
for 15 minutes and centrifugation for 30 minutes, both at 4°C.
Aliquots of supernatant (containing protein bound '251-IGF-I)
were counted in a gamma counter. Nonconditioned medium
was assayed in parallel and was subtracted from total bound
radioactivity to determine specific IGF-I binding activity, ex-
pressed as a percentage of total cpm. Dose response curves
were generated by assaying three concentrations (10 to 100 d)
of culture medium in duplicate or triplicate. To determine
specificity of binding, displacement curves were generated by
co-incubation with either recombinant human IGF-I, recombi-
nant rat IGF-II (Collaborative Research) or bovine insulin
(Sigma).
Western ligand blotting
Unreduced samples of conditioned medium or normal rabbit
serum (Pci Freeze, Rogers, Arkansas, USA) were electro-
phoresed through a SDS 10% polyacrylamide gel and the
separated proteins were electrobiotted onto nitrocellulose fil-
ters. Filters were washed and labeled with '251-IGF-I overnight
at 4°C and visualized by autoradiography according to the
method of Hassenlopp et al [19]. Serum-free, insulin-free me-
dium conditioned by Buffalo rat liver cells was from N. Ross,
Case Western Reserve University.
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Results
Serial dilutions of culture medium (10 to 100 .tl) caused
dose-dependent inhibition of 1251-IGF-I binding to anti-IGF-I
serum approximately in parallel to synthetic human IGF-I (Fig.
1). To confirm that the IGF-I immunoreactivity in the condi-
tioned medium represented new synthesis rather than a carry-
over from the serum-containing medium, collecting duct cells
were cultured in multi-well dishes and allowed to achieve
confluence. The serum-containing medium was removed and
serum-free medium added. After 24 hours of incubation, the
medium was discarded, fresh serum-free medium was added,
and cultures were incubated for an additional 24 hours in the
absence or presence of cycloheximide (10 M). The IGF-l
immunoreactivity (mean SE of 10 wells from 2 experiments)
was 489 52 and 52 5 pg/b4 cells for control and cyclohex-
imide-treated cells respectively. There was no difference in cell
viability as assessed by trypan blue uptake between cyclohex-
imide-treated and control cultures.
To characterize the secreted IGF-I immunoreactive species
further, serum-free insulin-free culture medium conditioned by
collecting duct cells was concentrated by passage over an
octadecylsilane silica column and applied to a Sephadex G100
column equilibrated in a denaturing buffer: 6 mol/liter guani-
dine-HCIIO.03% Brij. The gel filtration fractions demonstrated
two major peaks and one smaller peak of IGF-I immunoreac-
tivity (Fig. 2). One peak, Peak I, coeluted with '251-IGF-I,
indicating a molecular weight of approximately 7.5 to 8 kD, the
size of native IGF-I. Peak I was further fractionated by reverse
phase HPLC. Analysis of the HPLC elution profile revealed a
single peak of IGF-I immunoreactivity eluting at 33 minutes
Fraction number
Fig. 2. Sephadex G-100 gel filtration elution profile (6 mollliter guani-
dine-HC!, 0.03% Br(j). Conditioned medium from cultured rabbit col-
lecting duct cells was acidified and concentrated by adsorption to and
elution from an octadecylsilane silica column. The sample was dis-
solved in 6 mol/liter guanidine-HCI and applied to a Sephadex G100
column (denaturing buffer). Fractions were assayed for IGF-I immuno-
reactivity. The elution positions of molecular weight markers are
indicated by the arrows. I, II and III indicate the three peaks of IGF-I
immunoreactivity. Abbreviations are: Vo, Void volume (blue dextran);
\Tj, 125J volume. To convert ng to pmol multiply by 0.13.
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Fig. 3. HPLC of gel filtered 7 to 8000-dalton IGF-I species (Peak I
from Figure 2). The dashed line indicates the concentration of acetoni-
true. To convert ng to pmol multiply by 0.13.
(Fig. 3). Since the presence of IGF-I binding proteins might
result in an artifactual increase in IGF-I immunoreactivity in the
double antibody RIA, we next examined the IGF-I binding
activity of the high molecular weight species (molecular wt
greater then 25 kD), peak II (Fig. 2). Fractions from this peak
were desalted by reverse phase chromatography, lyophilized,
redissolved in phosphate-buffered saline, and incubated with
'2514GF-I for two hours at 30°C. The mixture then was applied
to a Sephadex GiQO column equilibrated in a non-denaturing
buffer. Analysis of the gel filtration elution profile revealed that
most of the radioactivity was confined to a high molecular
weight region (Fig. 4); there was little radioactivity in the
fractions corresponding to 7.5 kD. When unlabeled IGF-I was
incubated with the putative binding species (Peak II from Fig. 2)
along with radiolabeled IGF-I, the major peak of radioactivity
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Fig. 1. IGF-I radioimmunoassay standard curve. Symbols are (—.)
synthetic human IGF-I; and (LI1----LJ) serial dilution of rabbit collecting
duct cell conditioned medium. To convert picograms to femtomoles,
multiply by 0.13.
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species of 30 and 25 kD (Fig. 6). The former was similar in size
to the single species observed with Buffalo rat liver cells.
Similar species as well as larger forms were observed in normal
rabbit serum.
These data indicate that cultured rabbit collecting duct cells
secrete IGF-I. Of the three species containing IGF-I immuno-
reactivity found in culture medium from these cells, one (Peak
I) had an apparent molecular weight of 7.5 kD. This 7.5 kD
0.1 1.0 10 100 1000 10000 species had the same of size (gel filtration) as IGF-I, and when
chromatographed based upon hydrophobicity (reverse phase
HPLC) appeared to be a single species. IGF-I mRNA species
have been identified in rat collecting duct [10]. These data
suggest that the 7.5 kD IGF-I immunoreactive species is IGF-I.
In addition to the 7.5 kD IGF-I species, high molecular weight
species (greater than 25 kD) containing apparent IGF-I immu-
noreactivity also were found. Since the fractionation procedure
appeared in fractions corresponding to 7.5 kD, indicating that (gel filtration chromatography) involved a denaturing buffer (6
the binding was specific for IGF-I. mol/liter guanidine HC1) that would dissociate IGF-I from its
The 10 kD peak, peak III from Figure 2, was then character- binding protein(s) and since IGF-I-binding species might result
ized further. To determine whether this species contained IGF-I in an artifactually high level of IGF-I immunoreactivity in the
binding activity, fractions from this peak were desalted by double antibody RIA by binding the radiolabeled IOF-! tracer,
reverse phase chromatography, lyophilized, redissolved in we tested these high molecular species (Peak II from Fig. 2) for
phosphate buffered saline, incubated with '251-IGF-I and chro- IGF-I binding activity. Incubation of the species of greater than
matographed as above. The gel filtration profile revealed that 25 kD with '251-IGF-I indicated that they had IGF-I-binding
the radioactivity eluted with the same mobility as the tracer activity; the diminution of '251-IGF-I binding when unlabeled
alone. When the 10 kD species were reduced with mercapto- IGF-I was added demonstrated the specificity of the binding.
ethanol and rechromatographed, the size of the peak of immu- Further, unreduced conditioned medium showed IGF-I binding
noreactivity was unchanged. activity as assessed by the charcoal absorption assay as well as
IGF-I binding activity of culture medium was characterized Western ligand analysis. The low molecular weight (25 to 35
utilizing a charcoal adsorption assay. Protein binding of radio- kD) IGF binding proteins in culture medium were similar in size
labeled IGF-I increased linearly with increasing amounts of to those observed in normal rabbit serum and to those elabo-
culture medium (10 to 100 pi; data not shown). Binding was rated by other cultured cells [6, 20]. Whether the smaller
specific for IGF-I and IGF-II; there was little displacement of IGF-binding species represents a degradation product of the
radiolabeled IGF-I by insulin (Fig. 5). Western ligand analysis larger species is unknown. Although secretion of IGF binding
of unreduced conditioned medium revealed two IGF-I binding proteins has been described in kidney cells of mesenchymal
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Fig. 4. Sephadex gel filtration elution profile (phosphate-buffered sa-
line) of the Peak Jifraction from Figure 2 incubated with '251-IGF-I for
two hours at 30°C in the absence (0) orpresence (•) of excess unlabeled
IGF-I. The elution positions of molecular weight markers are indicated
by the arrows. Abbreviations are: Vo, void volume (blue dextran); Vi,
125J volume.
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Fig. 6. Autoradiograph of Western ligand blot of conditioned medium
from Buffalo rat liver cells (lane 1), normal rabbit serum (lane 2) and
rabbit collecting duct cells (lane 3). Samples of conditioned medium
(Buffalo rat liver cells I id; collecting duct cells 5 id) and serum (0.5 id)
were separated on a SDS-polyacrylamide gel (10%) by electrophoresis
under nonreducing conditions, blotted onto nitrocellulose, incubated
with '251-IGF-I and autoradiographed.
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Fig. 5. Competition curves for '251-IGF-I binding to conditioned me-
dium. Incubations and the charcoal adsorption assays were performed
as described in methods in the presence of IGF-I (0), IGF-II (.) or
insulin (A). Points represent the mean SE of 3 experiments.
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origin, mesangial cells [17, 211, this report constitutes the first
description of such proteins in renal epithelial cells, albeit under
conditions of tissue culture. Further studies will be required to
determine whether IGF binding proteins are expressed in the
collecting duct in vivo.
The presence of IGF-I binding protein in culture medium may
interfere with accurate measurement of IGF-I by RIA; the
IGF-I immunoreactivity in the culture medium most likely
reflects the presence of both IGF-I as well as IGF binding
proteins. The relative contributions of these two sources cannot
be determined by the gel filtration chromatographic column,
since the recovery of IGF-I binding proteins from the reverse
phase column is low [221. The co-elaboration of IGF-I and
IGF-I binding proteins is typical of many cell types [61. Al-
though the physiological role of IGF-I-binding protein(s) in the
kidney is not known, human fibroblasts, which also synthesize
IGF-I, recently were found to secrete specific binding protein(s)
that modulate the cellular binding and action of IGF-I [7—91.
The nature of the 10 kD species remains uncertain. The size
of this species was smaller than that of an IGF-I dimer and was
not altered by treatment with an agent that reduces disulfide
bonds. Binding activity of the 10 kD species was not detectable.
Since recovery of IGF-I binding proteins from the reverse
phase column is low, it may possess binding activity below the
threshold of detection in our procedure. However, no small
IGF-I binding species was observed by Western ligand analysis.
Thus, this 10 kD species may represent a high molecular weight
form of IGF-I—a precursor. The 10 kD size of this species is
consistent with putative precursors suggested by in vitro trans-
lation studies in the human and by analysis of the amino acid
sequences inferred from rat and human cDNAs [23, 24].
The in vivo relevance of our findings remains speculative, but
IGF-I may have a role in renal pathophysiology. Renal proximal
tubular cells and mesangial cells possess IGF-I receptors [15,
25—27]. IGF-I has been implicated in renal growth, as evidenced
by increased tissue IGF-I levels in postnephrectomy renal
hypertrophy and in the marked glomerular enlargement and
renal hypertrophy that occurs in acromegaly and in transgenic
mice that express the genes for growth hormone releasing
factor, growth hormone, or IGF-I [12, 28—301. Chronic but not
acute growth hormone administration increases glomerular
filtration rate and renal plasma flow, suggesting an indirect GH
effect, possibly mediated by IGF-I promotion [31]. In addition,
infusion of IGF-I results in an increase in the glomerular
filtration rate [311. Our findings confirm that collecting duct cells
synthesize IGF-I and demonstrate that these cells also secrete
IGF-I binding proteins. Since renal proximal tubular and
mesangial cells possess IGF-I receptors, these data suggest that
IGF-I may play a paracrine role in the regulation of renal
tubular cell growth and/or function. These studies also suggest
that cultured rabbit collecting duct cells constitute a useful in
vitro model system for studies of factors which regulate IGF-I
production.
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